A Comparative Study of Cosmetic Product in Subjects With Facial Acne During an Associated-treatment Phase Followed by a Maintenance Phase

Launched by PIERRE FABRE DERMO COSMETIQUE · Nov 29, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the effects of a new cosmetic product designed for people with facial acne. It aims to see how well this product works when used alongside a prescribed medical treatment for acne over a period of six months—three months while using both the medical treatment and the cosmetic product, followed by three months with just the cosmetic product. The study will also check how safe and tolerable the cosmetic product is for participants.

To be eligible for the study, participants should be between 14 and 24 years old and have mild to moderate facial acne. They must be starting a prescribed topical medical treatment and have a specific level of acne severity. The study is open to all genders. Participants can expect to use the product regularly and have their skin assessed throughout the trial. It's important to note that individuals with certain other skin conditions or who are changing their acne treatments during the study won't be able to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or Female aged between 14 and 24 years (included)
• • Subject with facial acne with score index severity IGA = 2 or 3, assessed on a scale ranged from 0 to 4.
• • Subject for whom a prescription of 12 weeks of a reference topical medical treatment is required from the day of the inclusion visit, for mild to moderate face acne
• Exclusion Criteria:
• Criteria related to the disease:
• • Facial skin disease other than acne, skin abnormalities, or dermatological condition on the face liable to interfere with the study assessments
• • Acne conglobata, Acne fulminans, nodulocystic acne or acneiform eruptions, according to investigator's assessment
• • Other type of pigmentation disorder than acne-related PIH liable to interfere with the study assessments according to the investigator
• Criteria related to treatments and/or products:
• • - Topical or oral treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy or cutaneous tolerance of the investigational products